Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-014
- Development stage
- Unknown
- Lead developer
- Serentrix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SER-014 (formerly PHE-377 or V-377) is an orally bioavailable, small-molecule antagonist of the transient receptor potential vanilloid 1 (TRPV1) channel. Originally developed by PharmEste and subsequently acquired by Serentrix, SER-014 is designed as a next-generation, thermally neutral TRPV1 antagonist that avoids the hyperthermia side effects commonly associated with first-generation compounds in this class. The drug has completed Phase 1 clinical trials in healthy volunteers, demonstrating a favorable safety and pharmacokinetic profile that supports twice-daily dosing. Serentrix is developing SER-014 for the treatment of neuropathic pain (neuralgia) and is also investigating its potential in preclinical models for endometriosis-associated pain.
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on SER-014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-014.